Chimeric receptors and methods and uses thereof

CN113150170BActive Publication Date: 2025-09-19KITE PHARMA INC +1
View PDF 27 Cites 1 Cited by

Patent Information

Application Number
CN202110248927.7
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Priority Date
2016-04-01
Filing Date
2017-03-31
Publication Date
2025-09-19
Estimated Expiration
2037-10-12

AI Technical Summary

Technical Problem

Existing CAR-T cell therapies have issues with effectiveness and side effects in treating CLL-1-related diseases and conditions, and the development of new and improved therapies is needed.

Method used

A chimeric antigen receptor (CAR) with specific binding to CLL-1 was designed, which contains a CLL-1 specific antigen binding molecule, an extracellular domain, a co-stimulatory domain and an activation domain. It uses a novel CD28 extracellular sequence and is introduced into immune cells through a specific vector such as a retroviral vector.

Benefits of technology

It enhances the ability of immune cells to recognize and kill CLL-1 target cells, improves the therapeutic effect and reduces side effects.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure GDA0005059304560000101
    Figure GDA0005059304560000101
  • Figure GDA0005059304560000211
    Figure GDA0005059304560000211
  • Figure GDA0005059304560000221
    Figure GDA0005059304560000221
Patent Text Reader

Abstract

Disclosed are antigen-binding molecules, chimeric receptors, and engineered immune cells according to the present invention. The present invention also relates to vectors, compositions, and treatment and / or detection methods using the antigen-binding molecules and engineered immune cells.
Need to check novelty before this filing date? Find Prior Art

Citation Information

Patent Citations

  • Composition and method of cancer antigen immunotherapy

    US20020006409A1

  • Beta-secretase crystals and methods for preparing and using the same

    US20040014194A1

  • Methods for inducing selective apoptosis

    US20110286980A1

  • Synthetic Multimerizing Agents

    US20120130076A1

  • Use of Chimeric Antigen Receptor-Modified T-Cells to Treat Cancer

    US20130287748A1

Cited By

  • Chimeric receptors and methods and uses thereof

    CN121108368A